

Darren R Feldman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8341688/darren-r-feldman-publications-by-year.pdf>
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158 papers	7,093 citations	40 h-index	81 g-index
172 ext. papers	8,963 ext. citations	5.6 avg, IF	5.45 L-index

#	Paper	IF	Citations
158	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. <i>Cell</i> , 2022 , 185, 563-575.e11	56.2	11
157	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101944	2.2	6
156	Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. <i>Annals of Surgery</i> , 2021 , 274, e1099-e1107	7.8	5
155	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021 , 26, 483-491	5.7	2
154	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. <i>Case Reports in Oncology</i> , 2021 , 14, 430-438	1	3
153	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 2910-2919	12.9	8
152	Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1129-1138	4	0
151	Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy. <i>Annals of Thoracic Surgery</i> , 2021 , 111, 1141-1149	2.7	1
150	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021 , 13, 96	14.4	8
149	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021 , 19, 1510-1521	6.6	2
148	Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors. <i>Investigational New Drugs</i> , 2021 , 39, 1656-1663	4.3	1
147	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 438.e1-438.e6		7
146	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1553-1562	2.2	13
145	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1563-1574	2.2	19
144	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e178-e183	3.3	1
143	Testicular Germ Cell Tumors Acquire Cisplatin Resistance by Rebalancing the Usage of DNA Repair Pathways. <i>Cancers</i> , 2021 , 13,	6.6	8
142	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4

141	Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24 900 Survivors. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa017	4.6	2
140	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1332-1337	2.2	4
139	Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3074-3075	2.2	
138	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy 2020 , 8,		20
137	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020 , 20, 84	2.2	7
136	Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. <i>Clinical Cancer Research</i> , 2020 , 26, 6550-6558	12.9	3
135	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6668-6676	15.9	15
134	The experience of hearing loss in adult survivors of childhood and young adult cancer: A qualitative study. <i>Cancer</i> , 2020 , 126, 1776-1783	6.4	5
133	Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). <i>Cancer</i> , 2020 , 126, 5311-5318	6.4	8
132	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. <i>Urology</i> , 2020 , 144, 111-116	1.6	2
131	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020 , 126, 5247-5255	6.4	10
130	Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa022	4.6	5
129	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 268-274.e1	3.3	18
128	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2329-2337	2.2	11
127	High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. <i>Journal of Neuro-Oncology</i> , 2019 , 142, 523-528	4.8	3
126	Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. <i>Clinical Cancer Research</i> , 2019 , 25, 4104-4116	12.9	15
125	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e678-e688	3.3	28
124	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , 2019 , 24, 1497-1501	5.7	11

123	Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 5913-5924	12.9	13
122	Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 459-468	7.3	6
121	Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1529-1554	7.3	62
120	Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	4
119	Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. <i>Histopathology</i> , 2019 , 74, 171-183	7.3	4
118	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience. <i>Urology</i> , 2019 , 124, 174-178	11.6	4
117	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019 , 5, 642-649	5.1	27
116	Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 12-17	2.8	17
115	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018 , 114, 133-138	1.6	6
114	Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. <i>Oncologist</i> , 2018 , 23, 316-323	5.7	23
113	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , 2018 , 118, 114-118	1.6	5
112	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , 2018 , 94, 115-125	7.5	179
111	Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e761-e769	3.3	15
110	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018 , 4, 986-994	5.1	20
109	Hearing Loss in Adult Survivors of Childhood Cancer Treated with Radiotherapy. <i>Children</i> , 2018 , 5,	2.8	5
108	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018 , 6, 758-765	12.5	66
107	Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 257-265	7.3	17
106	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , 2018 , 23, 3392-3406	10.6	200

105	Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors. <i>Blood</i> , 2018 , 132, 87-87	2.2	3
104	State-of-the-Art Management of Germ Cell Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 319-323	7.1	7
103	Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out. <i>Journal of Clinical Oncology</i> , 2018 , 36, 837-840	2.2	10
102	Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1505-1512	2.2	49
101	Testicular cancer. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 29	51.1	164
100	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018 , 4, 1228-1235	13.4	66
99	Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors. <i>Advances in Urology</i> , 2018 , 2018, 7272541	1.6	11
98	Variants in and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. <i>Clinical Cancer Research</i> , 2017 , 23, 3325-3333	12.9	47
97	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 532.e7-532.e13	2.8	17
96	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017 , 23, 703-713	50.5	1638
95	Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5757-5768	12.9	40
94	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e987-e994	3.3	34
93	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 2017 , 103, 154-160	1.6	9
92	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3525-3528	2.2	45
91	Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1211-1222	2.2	57
90	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , 2017 , 197, 391-397	2.5	6
89	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017 , 3, 590-598	5.1	21
88	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017 , 3, 421-427	5.1	29

87	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 591-597	2.2	434
86	Cisplatin Therapy Does Not Worsen Renal Function in Severe Antenatal Bartter Syndrome. <i>Case Reports in Nephrology and Dialysis</i> , 2017 , 7, 49-54	1.3	
85	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. <i>Journal of Clinical Oncology</i> , 2016 , 34, 345-51	2.2	49
84	Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer. <i>Journal of Urology</i> , 2016 , 195, 33-40	2.5	19
83	Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis. <i>European Urology</i> , 2016 , 70, 1082-1083	10.2	33
82	A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2016 , 21, 787-8	5.7	64
81	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 56-62	3.3	4
80	Variation in protein-coding sequence and the genetic basis of cisplatin-induced toxicities among testicular cancer survivors (TCS) in the Platinum Study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1537-1537 ^{2.2}	2.2	1
79	Genome-wide association study of cisplatin-induced peripheral neuropathy (CIPN) in testicular cancer survivors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4543-4543	2.2	2
78	Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2712-20	2.2	123
77	Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Urology</i> , 2016 , 95, 128-31	1.6	6
76	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2478-83	2.2	25
75	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3846-3853	2.2	55
74	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4000-4007	2.2	110
73	The Management of Advanced Germ Cell Tumors in 2016: The Memorial Sloan Kettering Approach. <i>Oncology</i> , 2016 , 30, 653-64	1.8	5
72	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 453-60	3.3	3
71	Development of a risk stratification system to guide treatment for female germ cell tumors. <i>Gynecologic Oncology</i> , 2015 , 138, 566-72	4.9	27
70	Late Relapse of Testicular Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2015 , 42, 359-68	2.9	22

69	Salvage high-dose chemotherapy for germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 355-62	2.8	10
68	Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3018-28	2.2	45
67	Interrogation of a context-specific transcription factor network identifies novel regulators of pluripotency. <i>Stem Cells</i> , 2015 , 33, 367-77	5.8	24
66	Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 59-66	3.3	29
65	Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. <i>Journal of Urology</i> , 2015 , 193, 513-8	2.5	12
64	Microwave ablation (MWA) for the treatment of a solitary, chemorefractory testicular cancer liver metastasis. <i>CardioVascular and Interventional Radiology</i> , 2015 , 38, 488-93	2.7	
63	Update in germ cell tumours. <i>Current Opinion in Oncology</i> , 2015 , 27, 177-84	4.2	12
62	Reply to L.C. Pagliaro et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2327-8	2.2	2
61	Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4510-4510	2.2	3
60	Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. <i>PLoS ONE</i> , 2015 , 10, e0142846	3.7	16
59	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 811-22	7.3	9
58	Epidemiology, Biology, and Genetics of Adult Male Germ Cell Tumors 2015 , 431-450		
57	Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. <i>Clinical Cancer Research</i> , 2014 , 20, 3712-20	12.9	75
56	Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. <i>Journal of Urology</i> , 2014 , 192, 415-9	2.5	34
55	Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 26.e9-15	2.8	18
54	Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	72
53	Treatment options for stage I nonseminoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3797-800	2.2	13
52	Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. <i>Annals of Oncology</i> , 2014 , 25, 663-668	10.3	57

51	The role of high-dose chemotherapy in the management of germ cell tumors. <i>Current Opinion in Oncology</i> , 2014 , 26, 284-93	4.2	2
50	Beyond stage I germ cell tumors: current status regarding treatment and long-term toxicities. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e180-90	7.1	5
49	Fertility preservation strategies for male patients with cancer. <i>Nature Reviews Urology</i> , 2013 , 10, 463-72	5.5	35
48	A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2013 , 31, 1016-22	4.3	38
47	Long-term response to sunitinib therapy for metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 297-302	3.3	40
46	The conundrum of clinical trials in adult germ-cell tumours. <i>Lancet Oncology</i> , 2013 , 14, 14-5	21.7	2
45	Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , 2013 , 119, 2574-81	6.4	21
44	Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors. <i>International Journal of Developmental Biology</i> , 2013 , 57, 273-80	1.9	54
43	Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4534-4534	2.2	1
42	Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 336-336	2.2	4
41	Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. <i>Cancer</i> , 2012 , 118, 981-6	6.4	44
40	Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2012 , 30, 335-40	4.3	73
39	Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. <i>Urology</i> , 2012 , 79, 361-4	1.6	16
38	Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. <i>Urology</i> , 2012 , 79, 156-9	1.6	20
37	Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site. <i>Urology</i> , 2012 , 79, 1079-84	1.6	5
36	The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. <i>European Journal of Cancer</i> , 2012 , 48, 340-6	7.5	40
35	Rare de novo germline copy-number variation in testicular cancer. <i>American Journal of Human Genetics</i> , 2012 , 91, 379-83	11	20
34	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012 , 118, 1868-76	6.4	100

33	Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. <i>Cancer</i> , 2012 , 118, 5078-83	6.4	26
32	The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. <i>Investigational New Drugs</i> , 2012 , 30, 1773-81	4.3	44
31	Late cardiovascular toxicity following chemotherapy for germ cell tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 537-44	7.3	40
30	Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. <i>PLoS ONE</i> , 2012 , 7, e51563	3.7	67
29	A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. <i>Hematology/Oncology Clinics of North America</i> , 2011 , 25, 557-76, viii -ix	3.1	10
28	Contemporary lymph node counts during primary retroperitoneal lymph node dissection. <i>Urology</i> , 2011 , 77, 368-72	1.6	12
27	Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update. <i>Urology</i> , 2011 , 77, 655-9	1.6	8
26	Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. <i>Journal of Cancer</i> , 2011 , 2, 374-7	4.5	43
25	Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 454-9	2.7	68
24	High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3466-73	2.2	300
23	High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1091-103	3.5	13
22	Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. <i>Oncologist</i> , 2011 , 16, 543-53	5.7	65
21	Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e740-e740	2.2	0
20	Testicular cancer survivorship: research strategies and recommendations. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1114-30	9.7	215
19	TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1706-13	2.2	150
18	Reply to B.I. Rini et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e286-e287	2.2	3
17	Natural immunity to pluripotency antigen OCT4 in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 8718-23	11.5	71
16	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2010 , 28, 523-8	4.3	55

15	Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , 2010 , 116, 5243-50	6.4	20
14	The approach to the patient with synchronous bilateral germ cell tumors: a lesson in oncologic prioritization. <i>Oncology</i> , 2010 , 24, 761-3	1.8	5
13	Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1432-9	2.2	268
12	Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5240-7	2.2	62
11	Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. <i>Clinical Cancer Research</i> , 2009 , 15, 7405-11	12.9	40
10	Good-risk-advanced germ cell tumors: historical perspective and current standards of care. <i>World Journal of Urology</i> , 2009 , 27, 463-70	4	7
9	Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008 , 6, 25-30	3.3	16
8	Treatment of stage I seminoma: is it time to change your practice?. <i>Journal of Hematology and Oncology</i> , 2008 , 1, 22	22.4	6
7	Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 595-600	4.7	5
6	Medical treatment of advanced testicular cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 672-84	27.4	253
5	Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?. <i>Nature Reviews Urology</i> , 2008 , 5, 78-9		1
4	Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2007 , 25, 487-90	4.3	20
3	Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 508-9		
2	Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 974-5; author reply 976-7	9.7	20
1	Novel targets and therapies for metastatic renal cell carcinoma. <i>Oncology</i> , 2006 , 20, 1745-53; discussion 1756	1.8	9